Course: Age-Related Eye Disease Study 2 (AREDS2), Section: More information and references

General

No CPD Points

Course Summary

John Lawrenson & Hugh Breakspear (15:33)

The Age‐Related Eye Disease Study was a large randomised controlled trial based in the United States which aimed to investigate whether supplementation with certain vitamins and minerals could slow or prevent the development of cataract and age‐related macular degeneration. This study concluded in 2001, but 2006 saw the launch of a second trial – the Age‐Related Eye Disease Study 2, or AREDS 2. The initial results were announced in May of 2013, and so in this interview Hugh Breakspear speaks to John Lawrenson, Professor of Clinical Optometry at City University, about AREDS 2 and discusses the implications of the reported findings for optometrists and patients.

First published in DOCET OQ87 (2013).

More information and references

References:

Chew EY et al (Age-Related Eye Disease Study 2 Research Group) (2013) Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 309 (19), 2005–15
Chew EY et al (Age-Related Eye Disease Study 2 Research Group) (2013) Lutein/Zeaxanthin for the Treatment of Age-Related Cataract: AREDS2 Randomized Trial Report No. 4. JAMA Ophthalmol 131 (7), 843–50
Evans JR, Lawrenson JG (2013) Dietary interventions for AMD: what do we know and what do we not know? Br J Ophthalmol. DOI: 10.1136/bjophthalmol-2013-303134
Lawrenson JG, Evans JR (2013) Advice about diet and smoking for people with or at risk of age-related macular degeneration: a cross-sectional survey of eye care professionals in the UK. BMC Public Health 2013 (13), 564